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genomes, suggested that a large number of poly‑
morphisms in mtDNA may be associated with 
more severe Brugada syndrome.
Considering that the heart, skeletal muscles, 
and the brain use a high number of mitochon‑
dria and that these tissues are essential compo‑
nents affected in the ATS triad, mtDNA poly‑
morphisms can be expected to partially influ‑
ence the disease phenotype.
In this article, we present results of our study 
aimed to identify higher mtDNA polymorphisms 
in HVR ‑I in 5 patients with ATS.
Methods Recruitment of participants Five 
study subjects together with their 4 mothers and 
3 fathers were enrolled. Based on clinical eval‑
uation and electrocardiographic examination, 
all study participants met the diagnostic crite‑
ria for ATS and were inhabitants of the states 
of the central and north central regions of Mex‑
ico. Patients 1, 2, and 3 were included owing 
to the presence of arrhythmia, history of limb 
weakness, facial features, and no history of sud‑
den cardiac death. Patient 4 was enrolled be‑
cause of sudden death of her twin sister and 
referred to the National Institute of Cardiolo‑
gy (Instituto Nacional de Cardiologia) because 
of suspicion of fatal arrhythmia.2 The ATS phe‑
notype was identified based on the presence of 
arrhythmia and long QT syndrome, the analy‑
sis of the facial phenotype, and history of sud‑
den death in the family. Patient 5 was includ‑
ed in the study but showed no cardiac involve‑
ment. The institutional review board approved 
the study, and the participants provided writ‑
ten informed consent.
Introduction Andersen–Tawil syndrome (ATS) 
is a heart rhythm disorder classified as type 7 
long QT syndrome and characterized by mus‑
cular, neurological, and skeletal involvement. So 
far, mutations in the KCNJ2 (60% of cases) and 
KCNJ5 (<1% of cases) genes have been reported 
to be the underlying cause of the disease.
In addition to the classic triad of periodic pa‑
ralysis, ventricular arrhythmias, and mild ‑to‑
‑moderate dysmorphism, some case reports also 
noted deficits in executive functioning skills, ab‑
stract reasoning,1 and seizures,2 which indicates 
that ATS affects the central nervous system. 
The clinical variability observed in the heart, 
skeletal muscles, and the brain could be a result 
of incomplete penetrance or interaction of mod‑
ifier genes, as seen in epilepsy.3 Given the back‑
ground, mitochondrial DNA (mtDNA) polymor‑
phisms can influence the phenotype by alter‑
ing the energy demand of the tissues affected 
in the triad of ATS.
The human mitochondrial genome includes 
16 569 base pairs (bps). They form a maternally 
inherited, double ‑stranded, circular DNA chain, 
which encodes 13 polypeptides—components 
of the respiratory chain complexes I, III, IV, and 
V. This genome is characterized by a high rate of 
mutations, which regularly affect coding sequences. 
The hypervariable sites I and II (HVR ‑I and HVR‑
‑II, respectively) are part of the D ‑loop, a triple‑
‑helix structure consisting of 1100 bps, which is 
located in mtDNA. The HVR ‑I site (approximate‑
ly 400 bps) is the most polymorphic, informative, 
and mutational hotspot used previously.4
Regarding heart rhythm disorders, Stoc‑
chi et al,5 who sequenced whole mitochondrial 
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Polymorphisms in the HVR ‑I site The polymor‑
phisms identified in 250 bps of the HRV ‑I site 
are shown in Supplementary material, Table S1. 
In the study patients with ATS, 14 polymor‑
phisms were found and compared with the Cam‑
bridge reference sequence. A significant differ‑
ence (P = 0.04) was found between patients and 
their healthy fathers after comparing polymor‑
phism distribution. Concordance was seen be‑
tween the T16189C polymorphisms in 3 patients 
and the C16223T, C16290T, and G16319A poly‑
morphisms in 2 individuals.
Multidimensional scaling plot A multidimen‑
sional scaling plot (Supplementary material, 
Figure S1) was established to identify an ances‑
tral relationship among patients and fathers in‑
cluded in the study. It showed that the mtDNA 
sequences of the study patients and their fathers 
were dispersed and no relationship was found 
among them. However, we observed a slight clus‑
tering between Patient 1 (p.Ser136Phe) and Pa‑
tient 4 (p Arg218Trp). The distance between 
their places of origin was approximately 340 
kilometers, and the ancestral relationship was 
unclear owing to lack of longer mitochondri‑
al DNA sequences. The polymorphisms iden‑
tified in the mothers were similar to those in 
the study patients.
The prevalence of ATS is unknown because 
of the limited number of patients diagnosed 
worldwide. Fortunately, in the last 10 years, 
a growing number of cases with their clinical 
characteristics have been reported in the litera‑
ture. Considering the high density of mitochon‑
dria in the heart, the brain, and skeletal mus‑
cles, we studied the HVR ‑I site (which is high‑
ly polymorphic) located in the mitochondrial 
genome to identify mtDNA polymorphisms in 
ATS and compare them with mtDNA polymor‑
phisms in patients’ fathers who could take part 
in the study. The results obtained were in line 
with previous studies, in which complete mito‑
chondrial genomes were sequenced in patients 
with Brugada syndrome and more polymor‑
phisms were found.5 The difference in the distri‑
bution of mtDNA polymorphisms may be indic‑
ative of a haplotype having more significant ef‑
fects on the synthesis of mitochondrial proteins.
Of note, the diagnosis of ATS without cardi‑
ac abnormalities remains a challenge. The fam‑
ily history of sudden death in some patients 
with ATS highlights the need for further stud‑
ies on the KCNJ2 gene mutations in the context 
of modifying factors and the necessity to use 
cardioverter ‑defibrillators in this population.6,7 
Altered protein synthesis in mitochondria, be‑
ing a consequence of polymorphisms in specific 
sites, may affect mitochondrial biogenesis lead‑
ing to the decreased effectiveness of the respira‑
tory chain and triggering acute episodes of limb 
weakness.8 Further studies on mitochondrial 
Genomic DNA extraction Five milliliters of whole 
blood were obtained from each patient, and DNA 
was extracted using the salting ‑out method.
The DNA integrity was assessed in a 1% aga‑
rose gel and quantified with the NanoDrop 2000 
Spectrophotometer (Thermo Fisher Scientific, 
Waltham, Massachusetts, United States) by mea‑
suring the ratio of absorbance at 260 nm and 280 
nm (approximately 1.8 accepted as appropriate).
Genotyping nuclear DNA Genetic testing for 
ATS verification was sponsored in 1 patient and 
performed with the use of massive parallel se‑
quencing for the KCNJ2, CACNA1C, and KCNQ1 
genes, provided by Sistemas Genómicos (Va‑
lencia, Spain). In the remaining 4 patients with 
ATS, DNA was analyzed by Sanger sequencing 
for the KCNJ2 gene, including all exons and in‑
tron / exon borders. When ATS was identified, 
cascade genetic screening was performed in 
the relatives who could participate in the study.
Genotyping mitochondrial DNA In order to iden‑
tify polymorphic positions in patients with ATS, 
the HVR ‑I region of mtDNA (400 bps) was am‑
plified and sequenced by the Sanger method us‑
ing the 5’‑ATACACCAGTCTTGTAAACC‑3’ and 
5’‑CACGGAGGATGGTGGTCAAG‑3’ primers. 
All the sequences obtained were aligned, and 
polymorphisms were identified using the DnaSP 
5.10.1 (Universitat de Barcelona, Barcelona, 
Spain) and MEGA 4.0 (Center of Evolutionary 
Functional Genomics Biodesign Institute, Ar‑
izona State University, Arizona, United States) 
software.
Statistical analysis Genotype frequencies 
were estimated by direct counting and distri‑
bution. Categorical variables were analyzed us‑
ing the Fisher exact or χ2 tests and performed 
with the R software, version 3.6.3 (R Founda‑
tion for Statistical Computing, Vienna, Austria).
A P value less than 0.05 was considered signif‑
icant. A 2‑dimensional scaling plot was drawn 
with the RStudio Desktop 1.2.5033 (RStudio, 
Inc., Boston, Massachusetts, United States) 
software using data from 250 bps of the HVR‑
‑I region and the Kimura 2‑parameter distance 
values obtained from the sequences (based on 
transition and transversion substitution rates), 
which summarized genetic distances between 
the study patients and their fathers. The Cam‑
bridge Reference Sequence was used as a refer‑
ence sequence in this study (GenBank number, 
NC_012920.1).
Results and discussion Genetic testing Five 
study participants were identified as carrying 
the following mutations located in the KCNJ2 
gene: p.Ser136Phe (Patient 1), p.Gly144Ala (Pa‑
tient 2), p.Arg218Trp (Patients 3 and 4), and 
p.Asp71Val (Patient 5) (TABLE 1).
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dynamics, regulatory pathways, and interac‑
tion between mitochondrial DNA with nuclear 
DNA in ATS are needed.
Research on ATS has captured the attention 
of basic and clinical scientists in recent years. 
However, it is still considered an exceptionally 
rare disease because of its infrequent identifi‑
cation at the tertiary care level. The analysis of 
extracardiac manifestations and their modify‑
ing genetic factors are issues currently investi‑
gated in ATS. This study suggested that the im‑
plication of mitochondrial polymorphisms and 
probably haplotypes may be one of the genet‑
ic factors influencing the classic triad of ATS.
SUPPLEMENTARY MATERIAL
Supplementary material is available at www.mp.pl/kardiologiapolska.
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TABLE 1 Clinical characteristics of patients with Andersen–Tawil syndrome and their relatives
Family status Sex Mutation LQT Facial phenotype Muscular 
involvement
Patient 1 F p.Ser136Phe No No Yes
Patient 2 F p.Gly144Ala No Yes Yes
Patient 3 M p.Arg218Trp No Yes Yes
Patient 4a F p.Arg218Trp Yes Yes Yes
Patient 5 F p.Asp71Val No Yes Yes
Mother 1 F – No No No
Mother 2 F – No No No
Mother 3 F – No No No
Mother 4 F p.Arg218Trp Yes Yes Yes
Father 2 M – No No No
Father 3 M – No No No
Father 4 M – No No No
a The patient participated in a previous study by Márquez et al.2
Abbreviations: F, female; M, male; LQT, long QT interval
